Article
Oncology
Eloisa Ruiz, Paula Moreno, Francisco Javier Gonzalez, Alba Maria Fernandez, Benito Cantador, Juan Luis Parraga, Angel Salvatierra, Antonio Alvarez
Summary: Lung transplant recipients are at high risk of developing malignancies, with de novo lung cancers being the most lethal, especially in patients with chronic obstructive pulmonary disease receiving single lung transplants. This study emphasizes the importance of considering the prevalence and impact of malignancies on long-term survival in lung transplant recipients.
Article
Urology & Nephrology
David Al-Adra, Talal Al-Qaoud, Kevin Fowler, Germaine Wong
Summary: Cancer is a significant concern after kidney transplantation, with poor outcomes once developed and limited screening and treatment strategies available for this high-risk population. Understanding patients' experiences and knowledge can help inform the epidemiology and burden of cancer in kidney transplant recipients.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2022)
Article
Medicine, General & Internal
Felix J. Krendl, Franka Messner, Claudia Boesmueller, Stefan Scheidl, Benno Cardini, Thomas Resch, Annemarie Weissenbacher, Rupert Oberhuber, Manuel Maglione, Stefan Schneeberger, Dietmar Oefner, Christian Margreiter
Summary: The study evaluated the incidence and impact of post-transplant malignancies (PTMs) following pancreas transplantation, with skin cancers being the most common type. Patients with solid organ and hematologic malignancies had a significantly higher risk of death compared to those with skin cancers following pancreas transplantation.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Zhuolun Song, Chong Dong, Xingchu Meng, Chao Sun, Kai Wang, Hong Qin, Chao Han, Yang Yang, Fubo Zhang, Weiping Zheng, Jing Chen, Keran Duan, Bowen Bi, Wei Gao
Summary: The study evaluated the efficacy of a perioperative prophylactic strategy against de novo HBV infection in pediatric LT recipients with HBcAb-positive grafts. The overall graft and recipient survival rates were similar in HBcAb-positive and HBcAb-negative graft recipients. The prophylactic targets for preventing de novo HBV infection in HBcAb-positive liver graft recipients were successfully achieved in most cases, significantly reducing the infection rate.
LIVER TRANSPLANTATION
(2021)
Article
Medicine, General & Internal
Ramin Raul Ossami Saidy, Franziska Eurich, Maximilian Paul Postel, Eva Maria Dobrindt, Jasper Feldkamp, Selina Johanna Schaper, Johann Pratschke, Brigitta Globke, Dennis Eurich
Summary: De novo hepatitis B in liver transplant patients is a rare complication, but if recognized and managed in a timely manner within a regular follow-up schedule, it can be well controlled without significant fibrosis progression or graft loss.
MEDICINA-LITHUANIA
(2021)
Article
Medicine, General & Internal
Boyeon Kim, Minjin Kang, Yoonjung Kim, Hyung Soon Lee, Banseok Kim, Jung Jun Lee, Yongjung Park, Kyung-A Lee
Summary: Improved patient care and immunosuppressive drugs have increased kidney transplantation (KT) rates, but also led to a higher incidence of cancer in KT recipients. Prostate and thyroid cancers were found to be the most common types, with Kaposi's sarcoma showing the highest standardized incidence ratio. Factors such as age over 39 and the use of prednisolone were associated with an increased risk of cancer development in KT patients under immunosuppressive conditions.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Hyo-In Choi, Do-Yoon Kang, Min-Seok Kim, Sang Eun Lee, Jung-Min Ahn, Jong-Young Lee, Yong-Hak Kim, Duk-Woo Park, Sung-Ho Jung, Jae-Joong Kim
Summary: Long-term immunosuppression with EVL was found to attenuate CAV progression for up to 5 years, based on IVUS follow-up. Furthermore, EVL showed comparable long-term clinical outcomes to CSA- or TAC-based protocols.
Article
Immunology
Jasmin Mucha, Ara Cho, Anna Marianne Weijler, Moritz Muckenhuber, Amun Georg Hofmann, Markus Wahrmann, Andreas Heinzel, Birgit Linhart, Pia Gattinger, Rudolf Valenta, Gabriela Berlakovich, Andreas Zuckermann, Peter Jaksch, Rainer Oberbauer, Thomas Wekerle
Summary: This study aims to determine the frequency of pre-existing and de novo anti-HLA IgE antibodies in solid organ transplant recipients. The study found that anti-HLA IgE antibodies occur at low frequency in kidney, liver, heart, and lung transplant recipients and are associated with sensitization at the IgG level.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Surgery
Lin Ma, Ming Li, Ting Zhang, Jia-Qi Xu, Xue-Bin Cao, Shan-Shan Wu, Li-Ying Sun
Summary: This meta-analysis aimed to evaluate the incidence of de novo autoimmune hepatitis (AIH) in children and adolescents with increased autoantibodies after liver transplantation. It found that the incidence of de novo AIH was around 9%, with a significant correlation between the incidence of de novo AIH and the rate of increase of antibodies to liver/kidney microsome (anti-LKM). Publications not using the International Autoimmune Hepatitis Group (IAIHG) criteria tended to have a higher incidence of de novo AIH.
TRANSPLANT INTERNATIONAL
(2021)
Article
Medicine, General & Internal
Jan Bednarsch, Zoltan Czigany, Lara R. Heij, Dong Liu, Marcel den Dulk, Georg Wiltberger, Philipp Bruners, Tom Florian Ulmer, Ulf Peter Neumann, Sven Arke Lang
Summary: For patients with iCCA, preoperative radiological characteristics play a crucial role in predicting survival and recurrence-free survival. Patients with a single iCCA <= 3 cm demonstrate better overall survival and recurrence-free survival outcomes.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Clinical Neurology
Jan Rusz, Tereza Tykalova, Michal Novotny, David Zogala, Karel Sonka, Evzen Ruzicka, Petr Dusek
Summary: This study identified three distinct speech subtypes in treatment-naive patients with PD, including prosodic, phonatory-prosodic, and articulatory-prosodic subtypes. Untreated controls with PD showed deteriorated speech over 1 year, while long-term dopaminergic medication maintained stable speech impairment severity in some subtypes and improved speech performance in others.
Article
Immunology
Tine Holm Riis, Dina Leth Moller, Julie Hogh, Andreas Dehlbaek Knudsen, Andreas Arendtsen Rostved, Delal Akdag, Nikolai Kirkby, Ulrik Lassen, Allan Rasmussen, Jens G. G. Hillingso, Hans-Christian Pommergaard
Summary: This study investigated the cumulative incidence of de novo cancer in Danish liver transplant recipients. It was found that 12% of the recipients developed de novo cancer after liver transplantation, with non-melanoma skin cancer being the majority. The 5-year cumulative incidences for all cancers and non-skin cancers were 10.7% and 4.9%, respectively. Thus, further larger studies are needed to identify the risk factors for de novo cancer after liver transplantation.
Article
Surgery
Nada El-domiaty, Faouzi Saliba, Mylene Sebagh, Chady Salloum, Eric Vibert, Daniel Azoulay, Jocelyne Hamelin, Daniel Cherqui, Rene Adam, Didier Samuel
Summary: This case study highlights the importance of long-term close surveillance of the liver graft even in the absence of viral recurrence and graft cirrhosis. A rare occurrence of de novo hepatocellular carcinoma in a non-cirrhotic allograft with no previous history of hepatic malignancy in either the donor or recipient was reported, emphasizing the need for continued vigilance in post-transplant patients.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Surgery
Suk Kyun Hong, Sunho Choe, Nam-Joon Yi, Aesun Shin, Eun Kyung Choe, Kyung Chul Yoon, Kwang-Woong Lee, Kyung-Suk Suh
Summary: The study evaluated the long-term mortality of Korean live liver donors by comparing it with the mortality of the general population, finding that liver donors have slightly higher long-term mortality rates. The most common causes of death were suicide, cancer, and traffic accidents.
Review
Pediatrics
Chiara Bergamo, Emily Claire Argento, Stefania Giampetruzzi, Maristella Cutini, Francesco Ciabattoni, Giovanna Faggian, Paola Gaio, Luca Bosa, Mara Cananzi
Summary: Liver transplant recipients, especially children, have an increased risk of developing de novo food allergies after transplantation. This systematic review found that approximately 15% of pediatric LT recipients develop de novo FAs, with higher risk associated with younger age at transplantation and the use of tacrolimus immunosuppression.
FRONTIERS IN PEDIATRICS
(2022)
Article
Oncology
Salah-Eddin Al-Batran, Ralf-Dieter Hofheinz, Alexander Reichart, Claudia Pauligk, Caroline Schoenherr, Rudolf Schlag, Gabriele Siegler, Steffen Doerfel, Michael Koenigsmann, Mark-Oliver Zahn, Joerg Schubert, Ali Aldaoud, Heinz-Gert Hoeffkes, Holger Schulz, Lars Hahn, Jens Uhlig, Wolfgang Blau, Martina Stauch, Joerg Weniger, Martin Wolf, Lutz Jacobasch, Stephan Bildat, Juergen Wehmeyer, Nils Homann, Joerg Trojan, Oliver Waidmann, Thomas Fietz, Hans-Peter Feustel, Matthias Groschek, Jan Wierecky, Karin Waibel, Stefan Mahlmann, Uwe Schwindel, Uwe Peters, Gunter Schuch, Daniel Pink, Henning Eschenburg, Marcus-A. Woerns, Hans-Detlev Harich, Ludwig Fischer von Weikersthal, Klaus-Ulrich Daessler, Dirk M. Behringer, Helmut Messmann, Albrecht Kretzschmar, Eike Gallmeier, Helmut Forstbauer, Volker Kunzmann, Jens Papke, Petra Buechner-Steudel, Ursula Vehling-Kaiser, Christoph Springfeld, Arndt Vogel, Thomas J. Ettrich, Marina Schaaf, Gerrit zur Hausen, Thorsten Oliver Goetze
Summary: The study examined the quality of life of patients with metastatic pancreatic cancer receiving first-line chemotherapy, revealing a deterioration in quality of life within 4.7 months for most patients. Treatment with gemcitabine and nab-paclitaxel showed the ability to help maintain good quality of life for some patients.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Correction
Oncology
Jose J. G. Marin, Maria Giuseppina Prete, Angela Lamarca, Simona Tavolari, Ana Landa-Magdalena, Giovanni Brandi, Oreste Segatto, Arndt Vogel, Rocio I. R. Macias, Pedro M. Rodrigues, Adelaida La Casta, Joachim Mertens, Cecilia M. P. Rodrigues, Maite G. Fernandez-Barrena, Ana Da Silva Ruivo, Marco Marzioni, Giulia Mentrasti, Pilar Acedo, Patricia Munoz-Garrido, Vincenzo Cardinale, Jesus M. Banales, Juan W. Valle, John Bridgewater, Chiara Braconi
BRITISH JOURNAL OF CANCER
(2021)
Editorial Material
Gastroenterology & Hepatology
Arndt Vogel, Anna Saborowski
JOURNAL OF HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Laura Izquierdo-Sanchez, Angela Lamarca, Adelaida La Casta, Stefan Buettner, Kirsten Utpatel, Heinz-Josef Klumpen, Jorge Adeva, Arndt Vogel, Ana Lleo, Luca Fabris, Mariano Ponz-Sarvise, Raffaele Brustia, Vincenzo Cardinale, Chiara Braconi, Gianpaolo Vidili, Nigel B. Jamieson, Rocio Ir Macias, Jan Philipp Jonas, Marco Marzioni, Waclaw Holowko, Trine Folseraas, Juozas Kupcinskas, Zeno Sparchez, Marcin Krawczyk, Lukasz Krupa, Viorel Scripcariu, Gian Luca Grazi, Ana Landa-Magdalena, Jan Nm Ijzermans, Katja Evert, Joris Erdmann, Flora Lopez-Lopez, Anna Saborowski, Alexander Scheiter, Alvaro Santos-Laso, Guido Carpino, Jesper B. Andersen, Jose Jg Marin, Domenico Alvaro, Luis Bujanda, Alejandro Forner, Juan W. Valle, Bas Groot Koerkamp, Jesus M. Banales
Summary: This study investigates the clinical course of cholangiocarcinoma in a pan-European cohort and finds that the disease is frequently diagnosed at an advanced stage and a proportion of patients fail to receive cancer-specific therapies, resulting in a poor prognosis.
JOURNAL OF HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Arndt Vogel, Martina Sterneck, Florian Vondran, Oliver Waidmann, Ingo Klein, Udo Lindig, Silvio Nadalin, Utz Settmacher, Frank Tacke, Hans Juergen Schlitt, Henning Wege
Summary: Multiple systemic therapy options have been approved for HCC treatment, with immuno-oncology combination therapies showing impressive response rates. However, using immunotherapeutics in the context of liver transplantation may increase the risk of rejection.
ZEITSCHRIFT FUR GASTROENTEROLOGIE
(2022)
Article
Oncology
Ambreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, Matthias Pinter, Lorenz Balcar, Bernhard Scheiner, Thomas U. Marron, Tomi Jun, Anwaar Saeed, Hannah Hildebrand, Mahvish Muzaffar, Musharraf Navaid, Abdul Rafeh Naqash, Anuhya Gampa, Umut Ozbek, Junk-Yi Lin, Ylenia Perone, Bruno Vincenzi, Marianna Silletta, Anjana Pillai, Yinghong Wang, Uqba Khan, Yi-Hsiang Huang, Dominik Bettinger, Yehia I. Abugabal, Ahmed Kaseb, Tiziana Pressiani, Nicola Personeni, Lorenza Rimassa, Naoshi Nishida, Luca Di Tommaso, Masatoshi Kudo, Arndt Vogel, Francesco A. Mauri, Alessio Cortellini, Rohini Sharma, Antonio D'Alessio, Celina Ang, David J. Pinato
Summary: The study found that blood inflammatory markers can predict the survival and response of patients with advanced hepatocellular carcinoma treated with immunotherapy. Neutrophile to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were identified as independent prognostic factors.
Article
Oncology
Cornelia L. A. Dewald, Mia-Maria Warnke, Roland Bruening, Martin A. Schneider, Peter Wohlmuth, Jan B. Hinrichs, Anna Saborowski, Arndt Vogel, Frank K. Wacker
Summary: Percutaneous hepatic perfusion (PHP) with melphalan delivers high-dose chemotherapy to hepatic tumors while minimizing systemic toxicity. This study examined the safety, response to therapy, and survival of patients with liver-dominant metastatic uveal melanoma (UM) treated with PHP. The study analyzed a total of 66 patients with liver-dominant metastasized uveal melanoma treated with 145 PHP, and found an overall response rate (ORR) of 59% and disease control rate (DCR) of 93.4%. The median hepatic progression-free survival (PFS) was 12.4 months and median overall survival (OS) was 18.4 months. Adverse events (AEs) included hematologic toxicity and hepatic toxicity, as well as cardiovascular events. In conclusion, PHP is a safe and effective salvage treatment for liver-dominant metastatic uveal melanoma, but careful patient selection is required due to rare serious AEs.
Article
Gastroenterology & Hepatology
Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Ann-Lii Cheng, Arndt Vogel, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Carlos Lopez Lopez, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong-Won Park, Daniel Palmer, Toshiyuki Tamai, Kenichi Saito, Corina E. Dutcus, Riccardo Lencioni
Summary: The study aimed to validate objective response as an independent predictor of overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC) receiving systemic anti-angiogenic therapy. The results showed that objective response assessed by investigator-assessed mRECIST could predict the survival of patients. Further studies are needed to confirm this finding.
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Gajanan Kendre, Karthikeyan Murugesan, Tilman Brummer, Oreste Segatto, Anna Saborowski, Arndt Vogel
Summary: This study retrospectively analyzed the genomic data of 6,130 patients diagnosed with intrahepatic cholangiocarcinoma (iCCA), and identified seven oncogenic driver genes and their co-mutational patterns. The study also discovered genetic variations and genomic patterns associated with iCCA, which are important for developing effective treatment strategies and predicting mechanisms of resistance.
JOURNAL OF HEPATOLOGY
(2023)
Review
Oncology
Arndt Vogel, Robin Katie Kelley, Philip Johnson, Philippe Merle, Thomas Yau, Masatoshi Kudo, Tim Meyer, Lorenza Rimassa
Summary: A systematic literature review reveals the importance of liver function assessments in predicting disease prognosis and response to systemic anticancer therapy in patients with advanced hepatocellular carcinoma. The study supports liver function as a prognostic marker and highlights the value of stratifying patients based on baseline liver function in clinical trials for aHCC.
Article
Oncology
Yue Linda Wu, Claudia Angela Maria Fulgenzi, Antonio D'Alessio, Jaekyung Cheon, Naoshi Nishida, Anwaar Saeed, Brooke Wietharn, Antonella Cammarota, Tiziana Pressiani, Nicola Personeni, Matthias Pinter, Bernhard Scheiner, Lorenz Balcar, Yi-Hsiang Huang, Samuel Phen, Abdul Rafeh Naqash, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Dominik Bettinger, Arndt Vogel, Martin Schoenlein, Johann von Felden, Kornelius Schulze, Henning Wege, Peter R. Galle, Masatoshi Kudo, Lorenza Rimassa, Amit G. Singal, Rohini Sharma, Alessio Cortellini, Vincent E. Gaillard, Hong Jae Chon, David J. Pinato, Celina Ang
Summary: Immunotherapy is the standard front-line therapy for advanced hepatocellular carcinoma, but many patients do not respond to it. This study evaluated the prognostic value of blood-based markers of inflammation and found that they may predict survival outcomes in patients treated with immunotherapy.
Letter
Gastroenterology & Hepatology
Tim Meyer, Sevasti Galani, Andre Lopes, Arndt Vogel
JOURNAL OF HEPATOLOGY
(2023)
Article
Oncology
Hans-Joachim Schmoll, Julia Mann, Fabian Meinert, Benjamin Garlipp, Kersten Borchert, Arndt Vogel, Eray Goekkurt, Ulrich Kaiser, Heinz-Gert Hoeffkes, Joern Ruessel, Stephan Kanzler, Thomas Edelmann, Helmut Forstbauer, Thomas Goehler, Carla Hannig, Bert Hildebrandt, Carsten Roll, Carsten Bokemeyer, Joerg Steighardt, Franziska Cygon, Stefan Ibach, Alexander Stein, Joseph Tintelnot
Summary: The study confirms the effectiveness and tolerability of FOLFOXIRI plus bevacizumab as a first-line treatment for mCRC, but challenges remain in its clinical implementation.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Sabrina Welland, Tiago deCastro, Melanie Bathon, Thomas Christian Wirth, Tanja Reineke-Plaass, Michael Saborowski, Ulrich Lehmann, Anna Saborowski, Arndt Vogel
Summary: This study aimed to evaluate the regulatory processes associated with off-label precision oncology treatments and found that a significant subset of GI cancer patients were able to benefit from targeted therapies identified through molecular testing. Despite some rejections, a considerable proportion of patients received targeted therapies and demonstrated treatment efficacy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Dominik Pfister, Nicolas Gonzalo Nunez, Roser Pinyol, Olivier Govaere, Matthias Pinter, Marta Szydlowska, Revant Gupta, Mengjie Qiu, Aleksandra Deczkowska, Assaf Weiner, Florian Muller, Ankit Sinha, Ekaterina Friebel, Thomas Engleitner, Daniela Lenggenhager, Anja Moncsek, Danijela Heide, Kristin Stirm, Jan Kosla, Eleni Kotsiliti, Valentina Leone, Michael Dudek, Suhail Yousuf, Donato Inverso, Indrabahadur Singh, Ana Teijeiro, Florian Castet, Carla Montironi, Philipp K. Haber, Dina Tiniakos, Pierre Bedossa, Simon Cockell, Ramy Younes, Michele Vacca, Fabio Marra, Jorn M. Schattenberg, Michael Allison, Elisabetta Bugianesi, Vlad Ratziu, Tiziana Pressiani, Antonio D'Alessio, Nicola Personeni, Lorenza Rimassa, Ann K. Daly, Bernhard Scheiner, Katharina Pomej, Martha M. Kirstein, Arndt Vogel, Markus Peck-Radosavljevic, Florian Hucke, Fabian Finkelmeier, Oliver Waidmann, Jorg Trojan, Kornelius Schulze, Henning Wege, Sandra Koch, Arndt Weinmann, Marco Bueter, Fabian Rossler, Alexander Siebenhuner, Sara De Dosso, Jan-Philipp Mallm, Viktor Umansky, Manfred Jugold, Tom Luedde, Andrea Schietinger, Peter Schirmacher, Brinda Emu, Hellmut G. Augustin, Adrian Billeter, Beat Muller-Stich, Hiroto Kikuchi, Dan G. Duda, Fabian Kutting, Dirk-Thomas Waldschmidt, Matthias Philip Ebert, Nuh Rahbari, Henrik E. Mei, Axel Ronald Schulz, Marc Ringelhan, Nisar Malek, Stephan Spahn, Michael Bitzer, Marina Ruiz de Galarreta, Amaia Lujambio, Jean-Francois Dufour, Thomas U. Marron, Ahmed Kaseb, Masatoshi Kudo, Yi-Hsiang Huang, Nabil Djouder, Katharina Wolter, Lars Zender, Parice N. Marche, Thomas Decaens, David J. Pinato, Roland Rad, Joachim C. Mertens, Achim Weber, Kristian Unger, Felix Meissner, Susanne Roth, Zuzana Macek Jilkova, Manfred Claassen, Quentin M. Anstee, Ido Amit, Percy Knolle, Burkhard Becher, Josep M. Llovet, Mathias Heikenwalder
Summary: The text discusses the impact of NASH on the development of HCC and the effect of immunotherapy, revealing the accumulation of exhausted and unconventionally activated CD8(+)PD1(+) T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, anti-PD1 treatment led to an increase in HCC, with CD8(+) T cells contributing to this increase.